CORT · Corcept Therapeutics Incorporated
Price
Snapshot
50 fields · last close| Market Cap | $8.56B |
| P/E | 146.78 |
| Float | 95.05M |
| Beta | 0.61 |
| Volatility 30D | 77.3% |
| Exchange | NASDAQ |
| Sector | Pharmaceuticals |
| Cap tier | Mid cap |
| Macro sensitivity | Moderate |
| Clavix score | 54.2 |
| Price | 73.28 |
| Change | −7.50% |
| Prev Close | 79.22 |
| Open | 84.98 |
| Day Low | 71.29 |
| Day High | 84.98 |
| Avg Vol | 1 |
| Avg $ Vol | $110.9M |
| 52W High | 126.38 |
| 52W Low | 28.66 |
| 52W Pos | 45.7% |
| From High | −42.02% |
| From Low | +155.69% |
| Max DD 1Y | −63.46% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −27.67% |
| SMA 50 | −33.03% |
| SMA 200 | −2.87% |
| RSI (14) | 23.8 |
| Vol 90D | 69.5% |
| Vol 1Y | — |
| 1Y Range | 29–126 |
| Daily bars | 549 |
| Perf Week | −8.18% |
| Perf Month | −33.75% |
| Perf Quarter | −26.61% |
| Perf Half Y | +51.91% |
| Perf Year | +6.81% |
| Perf YTD | +91.83% |
| Prev Day | −7.50% |
| Clavix | C |
| Debt / Eq | 0.07 |
| Curr Ratio | 2.92 |
| Int Cover | 19.8× |
| FCF Margin | 18.6% |
| Rev Growth | +12.8% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 14 / 14 |
Clavix risk grade
regraded every trading dayCORT grades C, 54.2 of 100. Steadiest on Sector Resilience (68), most exposed on Price Stability (34, weak). 2 of the 4 weighted dimensions sit above the Pharmaceuticals median. Ranks 14 of 14 in Pharmaceuticals by Clavix score.
How rough the ride is
| CORT | Pharmaceuticals median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.61 | 0.37 |
| 30-day realized volatilityannualized, from daily closes | 77.3% | 32.3% |
| Max drawdown, past yearworst peak-to-trough fall | −63.5% | — |
| Typical daily movemedian absolute daily change | 1.79% | — |
| Days beyond ±3%of the last 252 sessions | 73 (29%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| CORT | Pharmaceuticals median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.61 | 0.37 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Low 57% of 14 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Pharmaceuticals names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| CORT | |
|---|---|
| 1 week | −8.2% |
| 1 month | −33.7% |
| Year to date | +91.8% |
| 1 year | +6.8% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| CORT | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 28 Aug |
| Average score0 most bearish, 100 most bullish | 63 |
| Bullish · bearisharticles above 60 · below 40 | 20 · 6 |
| Directionarticles whose tone is improving vs worsening | 20 ↑ 6 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 14 Pharmaceuticals names Clavix covers; the tick is the sector median.
Growth
| CORT | |
|---|---|
| Revenue growthyear over year | +12.8% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Pharmaceuticals median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openCorcept reported third-quarter earnings and revenue above estimates. Year-over-year revenue growth was driven by strong Lifyorli uptake and higher Korlym sales as the company advanced its pipeline.
Corcept Therapeutics reported Q3 earnings of $1.01 per share, beating the Zacks consensus estimate of $0.68 and comparing with $0.16 a year earlier. The article says revenue also surpassed estimates, but it does not provide the revenue figure or other details.
Zacks Research lowered Corcept Therapeutics from a "strong-buy" rating to a "hold" in a Tuesday research note. The article provides no rationale or financial, operational, regulatory, or competitive details, so no concrete business implications can be derived.
Corcept reported that Part A of its Phase 2 BELLA trial, involving 95 women with ovarian cancer that no longer responded to platinum chemotherapy, found that Lifyorli plus nab-paclitaxel and bevacizumab produced longer median progression-free survival (time before the cancer grew or spread) and a higher objective response rate (the share of patients whose cancer responded) than the comparison treatments. No new safety problems were identified, although outcomes appeared strongest in patients who had not previously received bevacizumab.
Corcept reported positive results from Part A of its Phase 2 BELLA trial, which evaluated Lifyorli with nab-paclitaxel and bevacizumab in 95 patients with platinum-resistant ovarian cancer, meaning cancer that progressed during or soon after platinum-based chemotherapy. The excerpt gives no response rates, survival results, safety findings, or statistical measures showing the size of the benefit.
Nearest peers by size
Pharmaceuticals| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| AXSM | Axsome Therapeutics, Inc. | B | $7.21B | — | 0.84 | Compare |
| ELAN | Elanco Animal Health Incorporated | B | $12.65B | — | 1.75 | Compare |
| MANE | Veradermics, Incorporated | C | $5.70B | — | 0.30 | Compare |
| JAZZ | Jazz Pharmaceuticals PLC | A- | $15.06B | 15.93 | 0.36 | Compare |
| VTRS | Viatris Inc. | B+ | $21.86B | — | 0.87 | Compare |
| ZTS | Zoetis Inc | B+ | $32.94B | 12.85 | 0.65 | Compare |
| RPRX | Royalty Pharma PLC | A | $38.94B | 47.38 | 0.38 | Compare |
| BMY | Bristol-Myers Squibb Company | B+ | $131.2B | 13.93 | 0.14 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.